ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call Transcript
Thank you, operator, and good day, everyone. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR. Today, we issued a press release summarizing the top line results from the Phase II/III Illuminate trial, sepofarsen and CEP290 mediated LCA10. The press release can be found on our website at www.proqr.com.
With me today are Daniel de Boer, our Founder and CEO; and Dr. Aniz Girach, our Chief Medical Officer. Following their prepared remarks, Smital Shah, our Chief Business and Financial Officer, will join Daniel and Aniz for a Q&A session.
In order to include your question on today's call, we request that you dial into the telephone numbers provided in the press release. During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in ProQR, which are described in detail in our SEC filings.
I will now hand the call over to Daniel
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |